Preliminary in vitro evaluation of N′-(benzofuroxan-5-yl)methylene benzohydrazide derivatives as potential anti-Trypanosoma cruzi agents

MedChemComm

Volumn 3, Issue 7, 2012, Pages 824-828

  Jorge, Salomão Dória ^a   Ishii, Marina ^a   Palace Berl, Fanny ^a   Ferreira, Adilson Kleber ^b   Luiz De Sá Júnior, Paulo ^b   Alfredo De Oliveira, Alex ^a   Sonehara, Ieda Yuriko ^a   Pasqualoto, Kerly Fernanda Mesquita ^a   Tavares, Leoberto Costa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; BENZOFURAN DERIVATIVE; N' (BENZOFUROXAN 5 YL)METHYLENE BENZOHYDRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ELECTRON; EPIMASTIGOTE; HYDROPHOBICITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 84863667155     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c2md20019h     Document Type: Article

References (20)

1. N. Feasey M. Wansbrough-Jones D. C. W. Mabey A. W. Solomon Neglected tropical diseases Br. Med. Bull. 2010 93 179 200
2. L. C. Dias M. A. Dessoy J. J. N. Silva O. H. Thiemann G. Oliva A. D. Andricopulo Quimioterapia da doença de chagas: estado da arte e perspectivas no desenvolvimento de novos fármacos Quim. Nova 2009 32 2444 2457
3. A. Rassi Jr A. Rassi J. M. Marin-Neto Chagas disease Lancet 2010 375 1388
4. M. Moran J. Guzman A. Ropars A. McDonald N. Jameson B. Omune S. Ryan L. Wu Neglected disease research and development: how much are we really spending? PLoS Med. 2009 6 137
5. S. D. Jorge A. Masunari C. O. Rangel-Yagui K. F. M. Pasqualoto L. C. Tavares Design, synthesis, antimicrobial activity and molecular modeling studies of novel benzofuroxan derivatives against Staphylococcus aureus Bioorg. Med. Chem. 2009 17 3028
6. F. Palace-Berl A. Masunari S. D. Jorge C. A. Cechinel M. Ishii L. C. Tavares Topliss decision-tree approach applied in the design of new benzofuroxan derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus strains Braz. J. Pharm. Sci. 2009 45 67
7. H. Cerecetto M. González Synthetic medicinal chemistry in Chagas' disease: compounds at the final stage of "Hit-to-Lead" phase Pharmaceuticals 2010 3 810
8. P. N. Craig Interdependence between physical parameters and selection of substituent groups for correlation studies J. Med. Chem. 1971 14 680
9. L. P. Hammett Some relations between reaction rates and equilibrium constants Chem. Rev. 1935 17 125
10. C. Hansch and A. Leo, Exploring QSAR: Fundamentals and Applications in Chemistry and Biology, American Chemical Society, Washington, 1995
11. T. Fujita J. Iwasa C. Hansch A new substituent constant, π, derived from partition coefficients J. Am. Chem. Soc. 1964 86 5175
12. S. D. Jorge F. Palace-Berl A. Masunari C. A. Cechinel M. Ishii K. F. M. Pasqualoto L. C. Tavares Novel benzofuroxan derivatives against multidrug-resistant Staphylococcus aureus strains: design using Topliss' decision tree, synthesis and biological assay Bioorg. Med. Chem. 2011 19 5031
13. L. H. P. Silva V. Nussenzweig Sobre uma cepa de Trypanosoma cruzi virulenta para o camundongo branco Folia Clin. Biol. 1953 20 191
14. R. Devera X. Illarramendi R. Montoya-araújo C. Pirmez O. Fernandes J. R. Coura Biodemas de cepas do Trypanosoma cruzi isoladas de humanos de três áreas endêmicas de Minas Gerais Rev. Soc. Bras. Med. Trop. 2002 35 323
15. J. V. Arán C. Ochoa L. Boiani P. Buccino H. Cerecetto A. Gerpe M. Gonzáles D. Montero J. J. Nogal A. Gómez-Barrio A. Azqueta A. L. Ceráin O. E. Piro E. E. Castellano Synthesis and biological properties of new 5-nitroindazole derivatives Bioorg. Med. Chem. 2005 13 3197
16. J. F. Faucher T. Baltz K. G. Petry Detection of an "epimastigote- like" intracellular stage of Trypanosoma cruzi Parasitol. Res. 1995 81 441
17. R. Pozas J. Carballo C. Castro J. Rubio Synthesis and in vitro antitrypanosomal activity of novel nifurtimox analogues Bioorg. Med. Chem. Lett. 2005 15 1417
18. M. Rolón C. Vega J. A. Escario A. Gómez-Barrio Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes Parasitol. Res. 2006 99 103
19. M. Moreno D. A. D'ávila M. N. Silva L. M. C. Galvão A. M. Macedo E. Chiari E. D. Gontijo B. Zingales Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease Mem. Inst. Oswaldo Cruz 2010 105 918
20. Y. Totsuka T. Higuchi T. Imai A. Nishikawa T. Nohmi T. Kato S. Masuda N. Kinae K. Hiyoshi S. Ogo M. Kawanishi T. Yagi T. Ichinose N. Fukumori M. Watanabe T. Sugimura K. Wakabayashi Genotoxicity of nano/microparticles in in vitro micronuclei, in vivo comet and mutation assay systems Part. Fibre Toxicol. 2009 6 23